1. Pink Sheet
  2. >>Compliance
  3. >>Distribution/Supply Chain

The Quality Lowdown: The Effort Required To Stem Substandard, Illegitimate, Unapproved Drugs

 
• By Bowman Cox

As stakeholders in the US pharmaceutical distribution chain prepare to coordinate against suspect drugs, the world’s leading inspectorates collaborate on good distribution practices.

The Quality Lowdown
• Source: Pink Sheet illustration

An array of efforts to protect the public from substandard or illegitimate medicine in the US and around the world demonstrate the importance of vigilance and the high level of coordination it can require.

US pharmaceutical distribution stakeholders are working out the details of an intricate dance that begins in November to identify to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

UK Medicines Shortages Inquiry Eyes Full Reshoring of Drug Manufacturing

 
• By Neena Brizmohun

A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.

Big PBM Dominance Enabled By Affiliated Third Party Administrators Limiting Choices, FTC Told

 
• By Cathy Kelly

Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 
• By Sarah Karlin-Smith

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 
• By Eliza Slawther

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

More from Compliance